Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MRNA on watch again. Been an absolute great flipper. I think it pops again here soon.
KERX, bid building, think it breaks north soon.
KERX key downtrend line break here in the .16 area. Cleanly clear that and should see .20's
MRNA nice size bids now.
EGT 91k at .12 at the oprn today?!?! Looks like might reverse here
MDRNA Successfully Silences Gene Targets in Animal Models Using Novel UsiRNA Constructs
Proprietary DiLA2 Platform Achieves In Vivo Knockdown of Multiple Metabolic Targets and Demonstrates Safe and Effective Delivery in Repeat Dose Studies
* Monday February 23, 2009, 8:30 am EST
Related:
* MDRNA, Inc.
BOTHELL, WA--(MARKET WIRE)--Feb 23, 2009 -- MDRNA, Inc. (NasdaqGM:MRNA - News) announced today positive in vivo efficacy data on its proprietary UsiRNA constructs demonstrating a dose response which resulted in up to 90% knockdown of ApoB message in a rodent model. The data were presented by Michael V. Templin, Ph.D., Vice President, Discovery Research and Pharmaceutical Development of MDRNA, at the inaugural Informa Life Sciences TIDES Oligonucleotide and Peptide® Research, Technology and Product Development Conference in Tokyo, Japan.
Related Quotes
Symbol Price Change
MRNA 0.2799 0.0000
Chart for MDRNA, Inc.
{"s" : "mrna","k" : "c10,l10,p20,t10","o" : "","j" : ""}
"Our UsiRNA constructs offer a novel and proprietary means of providing highly potent siRNAs while increasing specificity," stated Barry Polisky, Ph.D., Chief Scientific Officer of MDRNA. "UsiRNAs were highly active in the mouse ApoB model for both message inhibition and serum cholesterol reduction. In these cases, UsiRNAs were fully compatible with RNAi machinery yet showed a substantial decrease in cytokine response. We are encouraged by these significant results and believe we have a unique siRNA construct to silence genes while minimizing potential side effects."
UsiRNAs are duplex siRNAs that are modified with non-nucleotide acyclic monomers, termed unlocked nucleobase analogs (UNA), in which the bond between two adjacent carbon atoms of ribose is removed. UsiRNAs are fully recognized by the RNAi machinery and provide for potent RNAi activity. Placement of UNA within UsiRNA minimizes the potential for off-target effects by the guide strand as well as undesired activity of the passenger strand. Further, the change in sugar structure renders this unlocked nucleobase analog conformationally flexible. The flexibility of the monomer escapes the surveillance mechanisms associated with cytokine induction, as well as providing protection from nuclease degradation.
MDRNA also reported new information on its DiLA2 Platform delivery technology:
"We are pleased to announce that our proprietary DiLA2 Platform achieved knockdown of two additional genes in liver tissue, DGAT2 and PCSK9, that are potentially important therapeutic targets, and the Platform continues to demonstrate safe and effective delivery following repeat systemic dosing of up to 9 mg/kg of siRNA formulations in mice," added Dr. Polisky. "The acute and repeat dose tolerability data of the DiLA2 Platform are promising. Repeat dosing on an every-third-day schedule for two weeks further indicates that DiLA2 liposomes are well tolerated. Our ability to deliver siRNAs to hepatocytes while achieving knockdown of multiple gene targets affirms our belief that the DiLA2 Platform represents a significant advancement in the development of a novel formulation for improved siRNA delivery."
"Our proprietary and novel UsiRNA constructs -- highly active siRNAs which minimize off-target activity -- represent a potential major step forward in the development of RNAi-based therapeutics," stated J. Michael French, President and Chief Executive Officer of MDRNA. "Further, our DiLA2 Platform continues to demonstrate its versatility in its ability to safely and efficiently deliver siRNAs against multiple gene targets and effectively silence those genes. The results reported today represent a further demonstration of the breadth and depth of our RNAi-based drug discovery engine and the capability and expertise of our scientific team."
About the DiLA2 Platform
The DiLA2 Platform is MDRNA's proprietary platform for creating novel liposomal delivery systems from amino acids. The platform enables MDRNA to tailor the charge, linker and acyl chains of amino acids in order to optimize the liposome for delivery to the target tissue of interest. In addition, the platform is designed to permit attachment of various peptides and other targeting molecules to improve a variety of delivery characteristics. In addition, MDRNA is utilizing peptides for nanoparticle formulations to increase cellular uptake and endosomal release.
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health by combining novel RNAi-based compounds and proprietary peptide- and liposomal-based drug delivery technologies to provide superior therapeutic options. Our multi-disciplinary portfolio of capabilities includes molecular biology, cellular biology, formulation expertise, peptide and alkylated amino acid chemistry, pharmacology, toxicology and bioinformatics. We are applying this expertise to a single, integrated drug discovery platform that will be the engine for our clinical pipeline and a versatile platform for establishing broad therapeutic partnerships. We are also building on new technologies, such as UsiRNAs that incorporate the non-nucleotide moiety Unlocked Nucleobase Analog (UNA) within the siRNA molecule, that we expect to lead to safer and more effective RNAi-based therapeutics. By combining broad expertise in siRNA science with proven delivery platforms and a strong and growing IP position, MDRNA is well positioned as a leading RNAi therapeutics company and value-added collaborator for our research partners. Additional information about MDRNA, Inc. is available at http://www.mdrnainc.com.
MDRNA Forward-Looking Statement
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of MDRNA or a subsidiary to obtain additional funding; (ii) the ability of MDRNA or a subsidiary to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of MDRNA, a subsidiary and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of MDRNA, a subsidiary and/or a partner to obtain required governmental approvals; and (v) the ability of MDRNA, a subsidiary and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in MDRNA's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. MDRNA assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Headed to .10 you think?
KERX, Huge bid on .14
MRNA looks like it's trying to turn back up here. Whackers seem to have figured out finally how stupid they are. .34 key break IMO
Well, the f'n gap is filled at least. A break of .34 should lead us back to the .40's.
I have know problem w/ selling on the spike, I did some. Your stupid not to. Can't understand anyones thought process to continually keep selling these small amounts down here when if you didn't want to hold any of the stock, you had all day Friday to get out in the .40's and .50's.
What the f is wrong with people. Couldn't get enough of this above .50 for awhile last friday. Now nobody wants it at .30 and they just keep pecking away at the bid. If you didn't want to hold any of this stock, why the hell weren't you selling in the .40 and .50's???
Something is just flat out wrong here.
.32 close, such bullchit
Was just thinking the same damn thing
Exaxctly! You hire a PR firm to give you this?? JD couldn't scribble this up himself?? What a joke.
You don't have to tell me that!
I work for a small company that does 200k acrossed it's fricken parts counter a month.
25% increase in revs don't mean jack when dealing with numbers like that.
Christ,if this is all the better Brass Bulls and the company have to offfer they might as well just keep there mouths shut. Rediculous
Get ready to load some more trip zero's IMO
.0013, 1 tick closer. I can taste that Osti Spumante already!
MRNA over 2.5 mil volume, second highest volume ever from what I can tell. Wish it would have consolidated higher though.
MRNA turning, EOD run starting
Well if there smart they won't short it much longer. Look for the cover
MRNA reloading some here
I expect an attack on the HOD yet today
MRNA crankin now .49 +95%
not done yet, volume coming in. News was great timing w/ the chart.
MRNA huuuuuge news, gapping bigly!!!
MDRNA, Inc. Announces Licensing Agreement With Roche
8:30a ET February 13, 2009 (Market Wire)
MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into an agreement with Roche (SWX: ROG) in which Roche will obtain a non-exclusive license to a portion of MDRNA's technology platform for the development of RNAi-based therapeutics. Terms of the agreement were not disclosed.
"We are pleased to have Roche recognize the value of our drug discovery platform," stated J. Michael French, President and Chief Executive Officer of MDRNA. "To have a portion of our platform in-licensed by Roche, a company with a significant effort in RNAi-based therapeutics, is a great testament to our intellectual property estate as well as the strong science being performed by our researchers. This agreement provides us the necessary resources to continue to pursue multiple, non-exclusive research collaborations, as well as future financing opportunities. We look forward to working with Roche to capitalize on the platform capability we are licensing to them as part of this agreement."
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Over the past decade, we have developed substantial capabilities in molecular biology, cellular biology, lipid chemistry, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide range of RNAi technologies and delivery approaches. These capabilities plus the in-licensing of key RNAi-related intellectual property have rapidly enabled us to become a leading RNAi-based therapeutics company with a pre-clinical pipeline in key therapeutic areas including oncology, metabolic disorders and inflammation. Through our capabilities, expertise and know-how, we are incorporating multiple RNAi technologies as well as peptide- and lipid-based delivery approaches into a single integrated drug discovery platform that will be the engine for our clinical pipeline as well as a versatile platform for establishing broad therapeutic partnerships with biotechnology and pharmaceutical companies. We are also investing in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics while aggressively building upon our broad and extensive intellectual property estate. By combining broad expertise in siRNA science with proven delivery platforms and a strong IP position, MDRNA is well positioned as a leading RNAi-based drug discovery and development company. Additional information about MDRNA, Inc. is available at http://www.mdrnainc.com.
MDRNA Forward-Looking Statement
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of MDRNA or a subsidiary to obtain additional funding; (ii) the ability of MDRNA or a subsidiary to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of MDRNA, a subsidiary and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of MDRNA, a subsidiary and/or a partner to obtain required governmental approvals; and (v) the ability of MDRNA, a subsidiary and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in MDRNA's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. MDRNA assumes no obligation to update and supplement forward-looking statements
G-dammit, I was gonna add yesterday but decided to wait till today. Phuck
MRNA huuuuuge news, gapping bigly!!!
MDRNA, Inc. Announces Licensing Agreement With Roche
8:30a ET February 13, 2009 (Market Wire)
MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into an agreement with Roche (SWX: ROG) in which Roche will obtain a non-exclusive license to a portion of MDRNA's technology platform for the development of RNAi-based therapeutics. Terms of the agreement were not disclosed.
"We are pleased to have Roche recognize the value of our drug discovery platform," stated J. Michael French, President and Chief Executive Officer of MDRNA. "To have a portion of our platform in-licensed by Roche, a company with a significant effort in RNAi-based therapeutics, is a great testament to our intellectual property estate as well as the strong science being performed by our researchers. This agreement provides us the necessary resources to continue to pursue multiple, non-exclusive research collaborations, as well as future financing opportunities. We look forward to working with Roche to capitalize on the platform capability we are licensing to them as part of this agreement."
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Over the past decade, we have developed substantial capabilities in molecular biology, cellular biology, lipid chemistry, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide range of RNAi technologies and delivery approaches. These capabilities plus the in-licensing of key RNAi-related intellectual property have rapidly enabled us to become a leading RNAi-based therapeutics company with a pre-clinical pipeline in key therapeutic areas including oncology, metabolic disorders and inflammation. Through our capabilities, expertise and know-how, we are incorporating multiple RNAi technologies as well as peptide- and lipid-based delivery approaches into a single integrated drug discovery platform that will be the engine for our clinical pipeline as well as a versatile platform for establishing broad therapeutic partnerships with biotechnology and pharmaceutical companies. We are also investing in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics while aggressively building upon our broad and extensive intellectual property estate. By combining broad expertise in siRNA science with proven delivery platforms and a strong IP position, MDRNA is well positioned as a leading RNAi-based drug discovery and development company. Additional information about MDRNA, Inc. is available at http://www.mdrnainc.com.
MDRNA Forward-Looking Statement
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of MDRNA or a subsidiary to obtain additional funding; (ii) the ability of MDRNA or a subsidiary to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of MDRNA, a subsidiary and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of MDRNA, a subsidiary and/or a partner to obtain required governmental approvals; and (v) the ability of MDRNA, a subsidiary and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in MDRNA's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. MDRNA assumes no obligation to update and supplement forward-looking statements
Sweeeeeeeeeeeeeeeet! Link back, don't say I didn't warn you!!!
MRNA huuuuuuge news and gapping. Link back for my alert yesterday.
MDRNA, Inc. Announces Licensing Agreement With Roche
8:30a ET February 13, 2009 (Market Wire)
MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into an agreement with Roche (SWX: ROG) in which Roche will obtain a non-exclusive license to a portion of MDRNA's technology platform for the development of RNAi-based therapeutics. Terms of the agreement were not disclosed.
"We are pleased to have Roche recognize the value of our drug discovery platform," stated J. Michael French, President and Chief Executive Officer of MDRNA. "To have a portion of our platform in-licensed by Roche, a company with a significant effort in RNAi-based therapeutics, is a great testament to our intellectual property estate as well as the strong science being performed by our researchers. This agreement provides us the necessary resources to continue to pursue multiple, non-exclusive research collaborations, as well as future financing opportunities. We look forward to working with Roche to capitalize on the platform capability we are licensing to them as part of this agreement."
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Over the past decade, we have developed substantial capabilities in molecular biology, cellular biology, lipid chemistry, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide range of RNAi technologies and delivery approaches. These capabilities plus the in-licensing of key RNAi-related intellectual property have rapidly enabled us to become a leading RNAi-based therapeutics company with a pre-clinical pipeline in key therapeutic areas including oncology, metabolic disorders and inflammation. Through our capabilities, expertise and know-how, we are incorporating multiple RNAi technologies as well as peptide- and lipid-based delivery approaches into a single integrated drug discovery platform that will be the engine for our clinical pipeline as well as a versatile platform for establishing broad therapeutic partnerships with biotechnology and pharmaceutical companies. We are also investing in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics while aggressively building upon our broad and extensive intellectual property estate. By combining broad expertise in siRNA science with proven delivery platforms and a strong IP position, MDRNA is well positioned as a leading RNAi-based drug discovery and development company. Additional information about MDRNA, Inc. is available at http://www.mdrnainc.com.
MDRNA Forward-Looking Statement
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of MDRNA or a subsidiary to obtain additional funding; (ii) the ability of MDRNA or a subsidiary to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of MDRNA, a subsidiary and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of MDRNA, a subsidiary and/or a partner to obtain required governmental approvals; and (v) the ability of MDRNA, a subsidiary and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in MDRNA's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. MDRNA assumes no obligation to update and supplement forward-looking statements
Just send the champagne when it does
MRNA look at those bollies pinching!!
Bullchit, he's paying up. If it would by chance get to .10 and he owns the shares he says he does, he should have no problem paying that debt up.
radar MRNA for a move soon. .30 key break imo
I really am expecting a move up yet this week. really liking the chart. MACD clean bullish crossover, bollies pinching hard, chi-osc uptrending and a nice close right at the 10 and 20 ma's and above the 5. Resistance at .27, .30, and .35ish with key trendline break aound .30.
This is headed to .0001. Is that better?
HAYZ critical area here, if it holds could bounce nicely back to .11 anyway
True
KERX, setting up to break this wedge again. bollies starting to pinch again
Might as well hold on to your money and your cans. Aluminum isn't worth chit now along with everything else! Collect the lows, sell them high, lol